Skip to main content
Premium Trial:

Request an Annual Quote

Celltrion Evaluating Crucell's Antibody, Protein Technology

NEW YORK (GenomeWeb News) – Celltrion will evaluate Crucell’s cell lines for use in its drug development services programs under a new licensing agreement, Crucell said today.
The non-exclusive agreement allows Celltrion to evaluate Crucell’s STAR technology, which is used in producing recombinant human antibodies and proteins, for its drug programs, Crucell said.
Crucell’s STAR technology contains genetic elements that enable stable gene expression that is used in making recombinant antibodies and proteins in mammalian cells. The Leiden, Netherlands-based firm said the technology can help increase the yields and lower the costs of antibody and protein production.
Celltrion offers services including cell line development and banking, process development, as well as technical, quality, and regulatory support services.
Financial terms of the agreement were not released.

The Scan

J&J Booster Support

A US Food and Drug Administration advisory panel has voted to support a booster dose of Johnson & Johnson's SARS-CoV-2 vaccine, according to the Los Angeles Times.

To Keep the Cases Moving

The president of the UK Royal College of Pathologists tells the Financial Times that more investment is needed to tackle a backlog of cases.

NAS Expels Archaeologist

Science reports Luis Jaime Castillo Butters' expulsion is the first of an international member from the US National Academy of Sciences.

PLOS Papers on Angelman Syndrome-Like Cases, Salmonella Paratyphi A, SARS-CoV-2 in Brazil

In PLOS this week: exome sequencing analysis of Angelman syndrome-like cases, genetic epidemiology of Salmonella Paratyphi A, and more.